Search

Your search keyword '"Li, Danan"' showing total 178 results
Start Over Author "Li, Danan"
178 results on '"Li, Danan"'

5. Supplementary Figures 1-13 from PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor

Author

Wang, Kai, primary, Zhang, Qin, primary, Li, Danan, primary, Ching, Keith, primary, Zhang, Cathy, primary, Zheng, Xianxian, primary, Ozeck, Mark, primary, Shi, Stephanie, primary, Li, Xiaorong, primary, Wang, Hui, primary, Rejto, Paul, primary, Christensen, James, primary, and Olson, Peter, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 4 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Author

Shimamura, Takeshi, primary, Perera, Samanthi A., primary, Foley, Kevin P., primary, Sang, Jim, primary, Rodig, Scott J., primary, Inoue, Takayo, primary, Chen, Liang, primary, Li, Danan, primary, Carretero, Julian, primary, Li, Yu-Chen, primary, Sinha, Papiya, primary, Carey, Christopher D., primary, Borgman, Christa L., primary, Jimenez, John-Paul, primary, Meyerson, Matthew, primary, Ying, Weiwen, primary, Barsoum, James, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 1 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Author

Shimamura, Takeshi, primary, Perera, Samanthi A., primary, Foley, Kevin P., primary, Sang, Jim, primary, Rodig, Scott J., primary, Inoue, Takayo, primary, Chen, Liang, primary, Li, Danan, primary, Carretero, Julian, primary, Li, Yu-Chen, primary, Sinha, Papiya, primary, Carey, Christopher D., primary, Borgman, Christa L., primary, Jimenez, John-Paul, primary, Meyerson, Matthew, primary, Ying, Weiwen, primary, Barsoum, James, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

8. Supplemental Materials and Methods from PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor

Author

Wang, Kai, primary, Zhang, Qin, primary, Li, Danan, primary, Ching, Keith, primary, Zhang, Cathy, primary, Zheng, Xianxian, primary, Ozeck, Mark, primary, Shi, Stephanie, primary, Li, Xiaorong, primary, Wang, Hui, primary, Rejto, Paul, primary, Christensen, James, primary, and Olson, Peter, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 3 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Author

Shimamura, Takeshi, primary, Perera, Samanthi A., primary, Foley, Kevin P., primary, Sang, Jim, primary, Rodig, Scott J., primary, Inoue, Takayo, primary, Chen, Liang, primary, Li, Danan, primary, Carretero, Julian, primary, Li, Yu-Chen, primary, Sinha, Papiya, primary, Carey, Christopher D., primary, Borgman, Christa L., primary, Jimenez, John-Paul, primary, Meyerson, Matthew, primary, Ying, Weiwen, primary, Barsoum, James, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 3 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Author

Shimamura, Takeshi, primary, Perera, Samanthi A., primary, Foley, Kevin P., primary, Sang, Jim, primary, Rodig, Scott J., primary, Inoue, Takayo, primary, Chen, Liang, primary, Li, Danan, primary, Carretero, Julian, primary, Li, Yu-Chen, primary, Sinha, Papiya, primary, Carey, Christopher D., primary, Borgman, Christa L., primary, Jimenez, John-Paul, primary, Meyerson, Matthew, primary, Ying, Weiwen, primary, Barsoum, James, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 6 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Author

Shimamura, Takeshi, primary, Perera, Samanthi A., primary, Foley, Kevin P., primary, Sang, Jim, primary, Rodig, Scott J., primary, Inoue, Takayo, primary, Chen, Liang, primary, Li, Danan, primary, Carretero, Julian, primary, Li, Yu-Chen, primary, Sinha, Papiya, primary, Carey, Christopher D., primary, Borgman, Christa L., primary, Jimenez, John-Paul, primary, Meyerson, Matthew, primary, Ying, Weiwen, primary, Barsoum, James, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table 4 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Author

Shimamura, Takeshi, primary, Perera, Samanthi A., primary, Foley, Kevin P., primary, Sang, Jim, primary, Rodig, Scott J., primary, Inoue, Takayo, primary, Chen, Liang, primary, Li, Danan, primary, Carretero, Julian, primary, Li, Yu-Chen, primary, Sinha, Papiya, primary, Carey, Christopher D., primary, Borgman, Christa L., primary, Jimenez, John-Paul, primary, Meyerson, Matthew, primary, Ying, Weiwen, primary, Barsoum, James, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 2 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Author

Shimamura, Takeshi, primary, Perera, Samanthi A., primary, Foley, Kevin P., primary, Sang, Jim, primary, Rodig, Scott J., primary, Inoue, Takayo, primary, Chen, Liang, primary, Li, Danan, primary, Carretero, Julian, primary, Li, Yu-Chen, primary, Sinha, Papiya, primary, Carey, Christopher D., primary, Borgman, Christa L., primary, Jimenez, John-Paul, primary, Meyerson, Matthew, primary, Ying, Weiwen, primary, Barsoum, James, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 5 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Author

Shimamura, Takeshi, primary, Perera, Samanthi A., primary, Foley, Kevin P., primary, Sang, Jim, primary, Rodig, Scott J., primary, Inoue, Takayo, primary, Chen, Liang, primary, Li, Danan, primary, Carretero, Julian, primary, Li, Yu-Chen, primary, Sinha, Papiya, primary, Carey, Christopher D., primary, Borgman, Christa L., primary, Jimenez, John-Paul, primary, Meyerson, Matthew, primary, Ying, Weiwen, primary, Barsoum, James, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Methods from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Author

Shimamura, Takeshi, primary, Perera, Samanthi A., primary, Foley, Kevin P., primary, Sang, Jim, primary, Rodig, Scott J., primary, Inoue, Takayo, primary, Chen, Liang, primary, Li, Danan, primary, Carretero, Julian, primary, Li, Yu-Chen, primary, Sinha, Papiya, primary, Carey, Christopher D., primary, Borgman, Christa L., primary, Jimenez, John-Paul, primary, Meyerson, Matthew, primary, Ying, Weiwen, primary, Barsoum, James, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 2 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Author

Shimamura, Takeshi, primary, Perera, Samanthi A., primary, Foley, Kevin P., primary, Sang, Jim, primary, Rodig, Scott J., primary, Inoue, Takayo, primary, Chen, Liang, primary, Li, Danan, primary, Carretero, Julian, primary, Li, Yu-Chen, primary, Sinha, Papiya, primary, Carey, Christopher D., primary, Borgman, Christa L., primary, Jimenez, John-Paul, primary, Meyerson, Matthew, primary, Ying, Weiwen, primary, Barsoum, James, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 1 from Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

Author

Shimamura, Takeshi, primary, Perera, Samanthi A., primary, Foley, Kevin P., primary, Sang, Jim, primary, Rodig, Scott J., primary, Inoue, Takayo, primary, Chen, Liang, primary, Li, Danan, primary, Carretero, Julian, primary, Li, Yu-Chen, primary, Sinha, Papiya, primary, Carey, Christopher D., primary, Borgman, Christa L., primary, Jimenez, John-Paul, primary, Meyerson, Matthew, primary, Ying, Weiwen, primary, Barsoum, James, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 4 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Author

Ji, Hongbin, primary, Wang, Zhenxiong, primary, Perera, Samanthi A., primary, Li, Danan, primary, Liang, Mei-Chih, primary, Zaghlul, Sara, primary, McNamara, Kate, primary, Chen, Liang, primary, Albert, Mitchell, primary, Sun, Yanping, primary, Al-Hashem, Ruqayyah, primary, Chirieac, Lucian R., primary, Padera, Robert, primary, Bronson, Roderick T., primary, Thomas, Roman K., primary, Garraway, Levi A., primary, Jänne, Pasi A., primary, Johnson, Bruce E., primary, Chin, Lynda, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure S3 from β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations

Author

Nakayama, Sohei, primary, Sng, Natasha, primary, Carretero, Julian, primary, Welner, Robert, primary, Hayashi, Yuichiro, primary, Yamamoto, Mihoko, primary, Tan, Alistair J., primary, Yamaguchi, Norihiro, primary, Yasuda, Hiroyuki, primary, Li, Danan, primary, Soejima, Kenzo, primary, Soo, Ross A., primary, Costa, Daniel B., primary, Wong, Kwok-Kin, primary, and Kobayashi, Susumu S., primary

Published
2023
Full Text
View/download PDF

20. Data from β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations

Author

Nakayama, Sohei, primary, Sng, Natasha, primary, Carretero, Julian, primary, Welner, Robert, primary, Hayashi, Yuichiro, primary, Yamamoto, Mihoko, primary, Tan, Alistair J., primary, Yamaguchi, Norihiro, primary, Yasuda, Hiroyuki, primary, Li, Danan, primary, Soejima, Kenzo, primary, Soo, Ross A., primary, Costa, Daniel B., primary, Wong, Kwok-Kin, primary, and Kobayashi, Susumu S., primary

Published
2023
Full Text
View/download PDF

21. Data from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Author

Ji, Hongbin, primary, Wang, Zhenxiong, primary, Perera, Samanthi A., primary, Li, Danan, primary, Liang, Mei-Chih, primary, Zaghlul, Sara, primary, McNamara, Kate, primary, Chen, Liang, primary, Albert, Mitchell, primary, Sun, Yanping, primary, Al-Hashem, Ruqayyah, primary, Chirieac, Lucian R., primary, Padera, Robert, primary, Bronson, Roderick T., primary, Thomas, Roman K., primary, Garraway, Levi A., primary, Jänne, Pasi A., primary, Johnson, Bruce E., primary, Chin, Lynda, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Methods and Legends from Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene

Author

Chen, Zhao, primary, Sasaki, Takaaki, primary, Tan, Xiaohong, primary, Carretero, Julian, primary, Shimamura, Takeshi, primary, Li, Danan, primary, Xu, Chunxiao, primary, Wang, Yuchuan, primary, Adelmant, Guillaume O., primary, Capelletti, Marzia, primary, Lee, Hyun Joo, primary, Rodig, Scott J., primary, Borgman, Christa, primary, Park, Seung-il, primary, Kim, Hyeong Ryul, primary, Padera, Robert, primary, Marto, Jarrod A., primary, Gray, Nathanael S., primary, Kung, Andrew L., primary, Shapiro, Geoffrey I., primary, Jänne, Pasi A., primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

23. Data from An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

Author

Schoeberl, Birgit, primary, Faber, Anthony C., primary, Li, Danan, primary, Liang, Mei-Chih, primary, Crosby, Katherine, primary, Onsum, Matthew, primary, Burenkova, Olga, primary, Pace, Emily, primary, Walton, Zandra, primary, Nie, Lin, primary, Fulgham, Aaron, primary, Song, Youngchul, primary, Nielsen, Ulrik B., primary, Engelman, Jeffrey A., primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Materials and Figure Legends 1-4 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Author

Ji, Hongbin, primary, Wang, Zhenxiong, primary, Perera, Samanthi A., primary, Li, Danan, primary, Liang, Mei-Chih, primary, Zaghlul, Sara, primary, McNamara, Kate, primary, Chen, Liang, primary, Albert, Mitchell, primary, Sun, Yanping, primary, Al-Hashem, Ruqayyah, primary, Chirieac, Lucian R., primary, Padera, Robert, primary, Bronson, Roderick T., primary, Thomas, Roman K., primary, Garraway, Levi A., primary, Jänne, Pasi A., primary, Johnson, Bruce E., primary, Chin, Lynda, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Methods, Figures 1-8, Table 1 from An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

Author

Schoeberl, Birgit, primary, Faber, Anthony C., primary, Li, Danan, primary, Liang, Mei-Chih, primary, Crosby, Katherine, primary, Onsum, Matthew, primary, Burenkova, Olga, primary, Pace, Emily, primary, Walton, Zandra, primary, Nie, Lin, primary, Fulgham, Aaron, primary, Song, Youngchul, primary, Nielsen, Ulrik B., primary, Engelman, Jeffrey A., primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 7 from Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

Author

Shimamura, Takeshi, primary, Li, Danan, primary, Ji, Hongbin, primary, Haringsma, Henry J., primary, Liniker, Elizabeth, primary, Borgman, Christa L., primary, Lowell, April M., primary, Minami, Yuko, primary, McNamara, Kate, primary, Perera, Samanthi A., primary, Zaghlul, Sara, primary, Thomas, Roman K., primary, Greulich, Heidi, primary, Kobayashi, Susumu, primary, Chirieac, Lucian R., primary, Padera, Robert F., primary, Kubo, Shigeto, primary, Takahashi, Masaya, primary, Tenen, Daniel G., primary, Meyerson, Matthew, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 3 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Author

Ji, Hongbin, primary, Wang, Zhenxiong, primary, Perera, Samanthi A., primary, Li, Danan, primary, Liang, Mei-Chih, primary, Zaghlul, Sara, primary, McNamara, Kate, primary, Chen, Liang, primary, Albert, Mitchell, primary, Sun, Yanping, primary, Al-Hashem, Ruqayyah, primary, Chirieac, Lucian R., primary, Padera, Robert, primary, Bronson, Roderick T., primary, Thomas, Roman K., primary, Garraway, Levi A., primary, Jänne, Pasi A., primary, Johnson, Bruce E., primary, Chin, Lynda, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 6 from Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

Author

Shimamura, Takeshi, primary, Li, Danan, primary, Ji, Hongbin, primary, Haringsma, Henry J., primary, Liniker, Elizabeth, primary, Borgman, Christa L., primary, Lowell, April M., primary, Minami, Yuko, primary, McNamara, Kate, primary, Perera, Samanthi A., primary, Zaghlul, Sara, primary, Thomas, Roman K., primary, Greulich, Heidi, primary, Kobayashi, Susumu, primary, Chirieac, Lucian R., primary, Padera, Robert F., primary, Kubo, Shigeto, primary, Takahashi, Masaya, primary, Tenen, Daniel G., primary, Meyerson, Matthew, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table from β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations

Author

Nakayama, Sohei, primary, Sng, Natasha, primary, Carretero, Julian, primary, Welner, Robert, primary, Hayashi, Yuichiro, primary, Yamamoto, Mihoko, primary, Tan, Alistair J., primary, Yamaguchi, Norihiro, primary, Yasuda, Hiroyuki, primary, Li, Danan, primary, Soejima, Kenzo, primary, Soo, Ross A., primary, Costa, Daniel B., primary, Wong, Kwok-Kin, primary, and Kobayashi, Susumu S., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 8 from Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

Author

Shimamura, Takeshi, primary, Li, Danan, primary, Ji, Hongbin, primary, Haringsma, Henry J., primary, Liniker, Elizabeth, primary, Borgman, Christa L., primary, Lowell, April M., primary, Minami, Yuko, primary, McNamara, Kate, primary, Perera, Samanthi A., primary, Zaghlul, Sara, primary, Thomas, Roman K., primary, Greulich, Heidi, primary, Kobayashi, Susumu, primary, Chirieac, Lucian R., primary, Padera, Robert F., primary, Kubo, Shigeto, primary, Takahashi, Masaya, primary, Tenen, Daniel G., primary, Meyerson, Matthew, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Methods, Legends for Figures 1-8 and Tables 1-3 from Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

Author

Shimamura, Takeshi, primary, Li, Danan, primary, Ji, Hongbin, primary, Haringsma, Henry J., primary, Liniker, Elizabeth, primary, Borgman, Christa L., primary, Lowell, April M., primary, Minami, Yuko, primary, McNamara, Kate, primary, Perera, Samanthi A., primary, Zaghlul, Sara, primary, Thomas, Roman K., primary, Greulich, Heidi, primary, Kobayashi, Susumu, primary, Chirieac, Lucian R., primary, Padera, Robert F., primary, Kubo, Shigeto, primary, Takahashi, Masaya, primary, Tenen, Daniel G., primary, Meyerson, Matthew, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

32. Data from Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene

Author

Chen, Zhao, primary, Sasaki, Takaaki, primary, Tan, Xiaohong, primary, Carretero, Julian, primary, Shimamura, Takeshi, primary, Li, Danan, primary, Xu, Chunxiao, primary, Wang, Yuchuan, primary, Adelmant, Guillaume O., primary, Capelletti, Marzia, primary, Lee, Hyun Joo, primary, Rodig, Scott J., primary, Borgman, Christa, primary, Park, Seung-il, primary, Kim, Hyeong Ryul, primary, Padera, Robert, primary, Marto, Jarrod A., primary, Gray, Nathanael S., primary, Kung, Andrew L., primary, Shapiro, Geoffrey I., primary, Jänne, Pasi A., primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figures 1-4, Tables 1-4 from Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene

Author

Chen, Zhao, primary, Sasaki, Takaaki, primary, Tan, Xiaohong, primary, Carretero, Julian, primary, Shimamura, Takeshi, primary, Li, Danan, primary, Xu, Chunxiao, primary, Wang, Yuchuan, primary, Adelmant, Guillaume O., primary, Capelletti, Marzia, primary, Lee, Hyun Joo, primary, Rodig, Scott J., primary, Borgman, Christa, primary, Park, Seung-il, primary, Kim, Hyeong Ryul, primary, Padera, Robert, primary, Marto, Jarrod A., primary, Gray, Nathanael S., primary, Kung, Andrew L., primary, Shapiro, Geoffrey I., primary, Jänne, Pasi A., primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 1 from Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

Author

Shimamura, Takeshi, primary, Li, Danan, primary, Ji, Hongbin, primary, Haringsma, Henry J., primary, Liniker, Elizabeth, primary, Borgman, Christa L., primary, Lowell, April M., primary, Minami, Yuko, primary, McNamara, Kate, primary, Perera, Samanthi A., primary, Zaghlul, Sara, primary, Thomas, Roman K., primary, Greulich, Heidi, primary, Kobayashi, Susumu, primary, Chirieac, Lucian R., primary, Padera, Robert F., primary, Kubo, Shigeto, primary, Takahashi, Masaya, primary, Tenen, Daniel G., primary, Meyerson, Matthew, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 1 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Author

Ji, Hongbin, primary, Wang, Zhenxiong, primary, Perera, Samanthi A., primary, Li, Danan, primary, Liang, Mei-Chih, primary, Zaghlul, Sara, primary, McNamara, Kate, primary, Chen, Liang, primary, Albert, Mitchell, primary, Sun, Yanping, primary, Al-Hashem, Ruqayyah, primary, Chirieac, Lucian R., primary, Padera, Robert, primary, Bronson, Roderick T., primary, Thomas, Roman K., primary, Garraway, Levi A., primary, Jänne, Pasi A., primary, Johnson, Bruce E., primary, Chin, Lynda, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 5 from Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

Author

Shimamura, Takeshi, primary, Li, Danan, primary, Ji, Hongbin, primary, Haringsma, Henry J., primary, Liniker, Elizabeth, primary, Borgman, Christa L., primary, Lowell, April M., primary, Minami, Yuko, primary, McNamara, Kate, primary, Perera, Samanthi A., primary, Zaghlul, Sara, primary, Thomas, Roman K., primary, Greulich, Heidi, primary, Kobayashi, Susumu, primary, Chirieac, Lucian R., primary, Padera, Robert F., primary, Kubo, Shigeto, primary, Takahashi, Masaya, primary, Tenen, Daniel G., primary, Meyerson, Matthew, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 3 from Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

Author

Shimamura, Takeshi, primary, Li, Danan, primary, Ji, Hongbin, primary, Haringsma, Henry J., primary, Liniker, Elizabeth, primary, Borgman, Christa L., primary, Lowell, April M., primary, Minami, Yuko, primary, McNamara, Kate, primary, Perera, Samanthi A., primary, Zaghlul, Sara, primary, Thomas, Roman K., primary, Greulich, Heidi, primary, Kobayashi, Susumu, primary, Chirieac, Lucian R., primary, Padera, Robert F., primary, Kubo, Shigeto, primary, Takahashi, Masaya, primary, Tenen, Daniel G., primary, Meyerson, Matthew, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

38. Data from Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

Author

Shimamura, Takeshi, primary, Li, Danan, primary, Ji, Hongbin, primary, Haringsma, Henry J., primary, Liniker, Elizabeth, primary, Borgman, Christa L., primary, Lowell, April M., primary, Minami, Yuko, primary, McNamara, Kate, primary, Perera, Samanthi A., primary, Zaghlul, Sara, primary, Thomas, Roman K., primary, Greulich, Heidi, primary, Kobayashi, Susumu, primary, Chirieac, Lucian R., primary, Padera, Robert F., primary, Kubo, Shigeto, primary, Takahashi, Masaya, primary, Tenen, Daniel G., primary, Meyerson, Matthew, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 2 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Author

Ji, Hongbin, primary, Wang, Zhenxiong, primary, Perera, Samanthi A., primary, Li, Danan, primary, Liang, Mei-Chih, primary, Zaghlul, Sara, primary, McNamara, Kate, primary, Chen, Liang, primary, Albert, Mitchell, primary, Sun, Yanping, primary, Al-Hashem, Ruqayyah, primary, Chirieac, Lucian R., primary, Padera, Robert, primary, Bronson, Roderick T., primary, Thomas, Roman K., primary, Garraway, Levi A., primary, Jänne, Pasi A., primary, Johnson, Bruce E., primary, Chin, Lynda, primary, and Wong, Kwok-Kin, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 4 from Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

Author

Shimamura, Takeshi, primary, Li, Danan, primary, Ji, Hongbin, primary, Haringsma, Henry J., primary, Liniker, Elizabeth, primary, Borgman, Christa L., primary, Lowell, April M., primary, Minami, Yuko, primary, McNamara, Kate, primary, Perera, Samanthi A., primary, Zaghlul, Sara, primary, Thomas, Roman K., primary, Greulich, Heidi, primary, Kobayashi, Susumu, primary, Chirieac, Lucian R., primary, Padera, Robert F., primary, Kubo, Shigeto, primary, Takahashi, Masaya, primary, Tenen, Daniel G., primary, Meyerson, Matthew, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 2 from Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance

Author

Shimamura, Takeshi, primary, Li, Danan, primary, Ji, Hongbin, primary, Haringsma, Henry J., primary, Liniker, Elizabeth, primary, Borgman, Christa L., primary, Lowell, April M., primary, Minami, Yuko, primary, McNamara, Kate, primary, Perera, Samanthi A., primary, Zaghlul, Sara, primary, Thomas, Roman K., primary, Greulich, Heidi, primary, Kobayashi, Susumu, primary, Chirieac, Lucian R., primary, Padera, Robert F., primary, Kubo, Shigeto, primary, Takahashi, Masaya, primary, Tenen, Daniel G., primary, Meyerson, Matthew, primary, Wong, Kwok-Kin, primary, and Shapiro, Geoffrey I., primary

Published
2023
Full Text
View/download PDF

43. HER2YVMA Drives Rapid Development of Adenosquamous Lung Tumors in Mice That Are Sensitive to BIBW2992 and Rapamycin Combination Therapy

Author

Perera, Samanthi A., Li, Danan, Shimamura, Takeshi, Raso, Maria G., Ji, Hongbin, Chen, Liang, Borgman, Christa L., Zaghlul, Sara, Brandstetter, Kathleyn A., Kubo, Shigeto, Takahashi, Masaya, Chirieac, Lucian R., Padera, Robert F., Branson, Roderick T., Shapiro, Geoffrey I., Greulich, Heidi, Meyerson, Matthew, Guertler, Ulrich, Chesa, Pilar Garin, Solca, Flavio, Wistuba, Ignacio I., Wong, Kwok-Kin, and Cavenee, Webster K.

Published
2009
Full Text
View/download PDF

45. Epidermal Growth Factor Receptor Variant III Mutations in Lung Tumorigenesis and Sensitivity to Tyrosine Kinase Inhibitors

Author

Ji, Hongbin, Zhao, Xiaojun, Yuza, Yuki, Shimamura, Takeshi, Li, Danan, Protopopov, Alexei, Jung, Boonim L., McNamara, Kate, Xia, Huili, Glatt, Karen A., Thomas, Roman K., Sasaki, Hidefumi, Horner, James W., Eck, Michael, Mitchell, Albert, Sun, Yangping, Al-Hashem, Ruqayyah, Bronson, Roderick T., Rabindran, Sridhar K., Discafani, Carolyn M., Maher, Elizabeth, Shapiro, Geoffrey I., Meyerson, Matthew, and Wong, Kwok-Kin

Published
2006
Full Text
View/download PDF

46. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

Author

Johnson, Neil, Li, Yu-Chen, Walton, Zandra E., Cheng, Katherine A., Li, Danan, Rodig, Scott J., Moreau, Lisa A., Unitt, Christine, Bronson, Roderick T., Thomas, Huw D., Newell, David R., D'Andrea, Alan D., Curtin, Nicola J., Wong, Kwok-Kin, and Shapiro, Geoffrey I.

Subjects
Phosphotransferases -- Physiological aspects -- Research, Phosphorylation -- Research, Cellular proteins -- Physiological aspects -- Research, Biological sciences, Health
Abstract

Cells that are deficient in homologous recombination, such as those that lack functional breast cancer-associated 1 (BRCA1) or BRCA2, are hypersensitive to inhibition of poly(ADP-ribose) polymerase (PARP). However, BRCA-deficient tumors represent only a small fraction of adult cancers, which might restrict the therapeutic utility of PARP inhibitor monotherapy. Cyclin-dependent kinase 1 (Cdk1) phosphorylates BRCA1, and this is essential for efficient formation of BRCA1 foci. Here we show that depletion or inhibition of Cdk1 compromises the ability of cells to repair DNA by homologous recombination. Combined inhibition of Cdk1 and PARP in BRCA-wild-type cancer cells resulted in reduced colony formation, delayed growth of human tumor xenografts and tumor regression with prolonged survival in a mouse model of lung adenocarcinoma. Inhibition of Cdk1 did not sensitize nontransformed cells or tissues to inhibition of PARP. Because reduced Cdk1 activity impaired BRCA1 function and consequently, repair by homologous recombination, inhibition of Cdk1 represents a plausible strategy for expanding the utility of PARP inhibitors to BRCA-proficient cancers., Cdk1 is a core component of the cell cycle machinery, and forms complexes with cyclins A and B to promote S, G2 and M phase progression (1-3). Cdkl and other [...]

Published
2011
Full Text
View/download PDF

47. A dual role for the immune response in a mouse model of inflammationassociated lung cancer

Author

Dougan, Michael, Li, Danan, Neuberg, Donna, Mihm, Martin, Googe, Paul, Wong, Kwok-Kin, and Dranoff, Glenn

Subjects
Interferon -- Analysis, Tumors -- Analysis, Inflammation -- Analysis, Immune response -- Analysis, Smoking -- Analysis, Lung cancer -- Analysis, Health care industry
Abstract

Lung cancer is the leading cause of cancer death worldwide. Both principal factors known to cause lung cancer, cigarette smoke and asbestos, induce pulmonary inflammation, and pulmonary inflammation has recently [...]

Published
2011
Full Text
View/download PDF

48. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Author

Zhou, Wenjun, Ercan, Dalia, Chen, Liang, Yun, Cai-Hong, Li, Danan, Capelletti, Marzia, Cortot, Alexis B., Chirieac, Lucian, Iacob, Roxana E., Padera, Robert, Engen, John R., Wong, Kwok-Kin, Eck, Michael J., Gray, Nathanael S., and Janne, Pasi A.

Subjects
Oncology, Experimental, Erlotinib -- Health aspects, Gefitinib -- Health aspects, Lung cancer, Non-small cell -- Drug therapy, Cancer -- Research, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation (1-3). Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are associated with toxicity due to concurrent inhibition of wild-type EGFR (4,5). All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR. Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR. T790M. These agents are 30- to 100-fold more potent against EGFR. T790M, and up to 100-fold less potent against wild-type EGFR., than quinazoline-based EGFR. inhibitors in vitro. They are also effective in murine models of lung cancer driven by EGFR. T790M. Co-crystallization studies reveal a structural basis for the increased potency and mutant selectivity of these agents. These mutant-selective irreversible EGFR kinase inhibitors may be clinically more effective and better tolerated than quinazoline-based inhibitors. Our findings demonstrate that functional pharmacological screens against clinically important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors., EGFR kinase inhibitors, gefitinib and erlotinib, are effective clinical therapies for NSCLCs that harbour activating mutations in the EGFR kinase domain (1,6). The most common EGFR mutations, L858R. and de1E746_A750, [...]

Published
2009
Full Text
View/download PDF

49. Predicting drug susceptibility of non--small cell lung cancers based on genetic lesions

Author

Sos, Martin L., Michel, Kathrin, Zander, Thomas, Weiss, Jonathan, Frommolt, Peter, Peifer, Martin, Li, Danan, Ullrich, Roland, Koker, Mirjam, Fischer, Florian, Shimamura, Takeshi, Rauh, Daniel, Mermel, Craig, Fischer, Stefanie, Stuckrath, Isabel, Heynck, Stefanie, Beroukhim, Rameen, Lin, William, Winckler, Wendy, Shah, Kinjal, LaFramboise, Thomas, Moriarty, Whei F., Hanna, Megan, Tolosi, Laura, Rahnenfuhrer, Jorg, Verhaak, Roel, Chiang, Derek, Getz, Gad, Hellmich, Martin, Wolf, Jurgen, Girard, Luc, Peyton, Michael, Weir, Barbara A., Chen, Tzu-Hsiu, Greulich, Heidi, Barretina, Jordi, Shapiro, Geoffrey I., Garraway, Levi A., Gazdar, Adi F., Minna, John D., Meyerson, Matthew, Wong, Kwok-Kin, and Thomas, Roman K.

Subjects
Gene mutations -- Health aspects, Genetic susceptibility -- Research, Heat shock proteins -- Health aspects, Heat shock proteins -- Genetic aspects, Heat shock proteins -- Research, Lung cancer, Non-small cell -- Risk factors, Lung cancer, Non-small cell -- Genetic aspects, Lung cancer, Non-small cell -- Care and treatment, Lung cancer, Non-small cell -- Research
Abstract

Somatic genetic alterations in cancers have been linked with response to targeted therapeutics by creation of specific dependency on activated oncogenic signaling pathways. However, no tools currently exist to systematically connect such genetic lesions to therapeutic vulnerability. We have therefore developed a genomics approach to identify lesions associated with therapeutically relevant oncogene dependency. Using integrated genomic profiling, we have demonstrated that the genomes of a large panel of human non--small cell lung cancer (NSCLC) cell lines are highly representative of those of primary NSCLC tumors. Using cell-based compound screening coupled with diverse computational approaches to integrate orthogonal genomic and biochemical data sets, we identified molecular and genomic predictors of therapeutic response to clinically relevant compounds. Using this approach, we showed that v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations confer enhanced Hsp90 dependency and validated this finding in mice with KRAS-driven lung adenocarcinoma, as these mice exhibited dramatic tumor regression when treated with an Hsp90 inhibitor. In addition, we found that cells with copy number enhancement of v-abl Abelson murine leukemia viral oncogene homolog 2 (ABL2) and ephrin receptor kinase and v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) (SRC) kinase family genes were exquisitely sensitive to treatment with the SRC/ABL inhibitor dasatinib, both in vitro and when it xenografted into mice. Thus, genomically annotated cell-line collections may help translate cancer genomics information into clinical practice by defining critical pathway dependencies amenable to therapeutic inhibition., Introduction The dynamics of ongoing efforts to fully annotate the genomes of all major cancer types are reminiscent of those of the Human Genome Project. The analysis of somatic gene [...]

Published
2009

50. LKB1 modulates lung cancer differentiation and metastasis

Author

Ji, Hongbin, Ramsey, Matthew R., Hayes, D. Neil, Fan, Cheng, McNamara, Kate, Kozlowski, Piotr, Torrice, Chad, Wu, Michael C., Shimamura, Takeshi, Perera, Samanthi A., Liang, Mei-Chih, Cai, Dongpo, Naumov, George N., Bao, Lei, Contreras, Cristina M., Li, Danan, Chen, Liang, Krishnamurthy, Janakiraman, Koivunen, Jussi, Chirieac, Lucian R., Padera, Robert F., Bronson, Roderick T., Lindeman, Neal I., Christiani, David C., Lin, Xihong, Shapiro, Geoffrey I., Jänne, Pasi A., Johnson, Bruce E., Meyerson, Matthew, Kwiatkowski, David J., Castrillon, Diego H., Bardeesy, Nabeel, Sharpless, Norman E., and Wong, Kwok-Kin

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results